Minimal residual disease: a target for radioimmunotherapy with 131I-labeled monoclonal antibodies? Some dosimetric considerations.
Sautter-Bihl
M L
ML
Department of Radiooncology and Nuclear Medicine, Klinikum Karlsruhe, Germany.
Herbold
G
G
Bihl
H
H
D000042:Absorption; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003198:Computer Simulation; D004735:Energy Transfer; D006801:Humans; D018796:Immunoconjugates / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008954:Models, Biological; D009010:Monte Carlo Method; D018365:Neoplasm, Residual / Q000532:radiotherapy*; D019047:Phantoms, Imaging; D016499:Radioimmunotherapy; D011879:Radiotherapy Dosage
D000911:Antibodies, Monoclonal; D018796:Immunoconjugates; D007457:Iodine Radioisotopes